News Sentiment

IRMD sentiment intelligence

Iradimed Co news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 59 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Medical Devices Read-through group
Latest close 97.20 Week of 10 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

80/100 classification confidence.

Company focus 48

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-3.7% over one week, +3.8% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Neutral

Should You Think About Buying IRADIMED CORPORATION (NASDAQ:IRMD) Now?

Market Reaction

Balanced read

60/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 80/100 classification
One-week reaction -3.7% Price reacting lower
Trend fit Trend inactive 3.8% over four weeks
Fair value 61.2% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 11
Neutral 41
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 48
Industry context 11
Sector context 0

Sources

Coverage mix

Publishers
Market source 12
TradingView 9
TradingKey 8
Stock Titan 5
simplywall.st 3
Finviz 2
StockStory 2
MT Newswires 2

Event Lens

What the news is about

Classified themes
Market update 32
Earnings 20
Capital return 3
Analyst action 2
Regulatory and legal 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-59 of 59
Investing.com South Africa Direct company coverage

Iradimed director sells $285,000 in company stock By Investing.com

A director at IRADIMED CORP, Hilda Frederique Scharen-Guivel, sold 3,000 shares of company stock for $285,000 on June 4, 2026. This transaction occurred amidst a strong 52% return for IRMD stock over the past year, though InvestingPro's Fair Value analysis suggests the shares may

Tone
Negative 33/100
Event
Market update
Published
05 Jun 2026 04:40
Source
Investing.com South Africa
GuruFocus Direct company coverage

Insider Sell: Hilda Scharen-guivel Sells 3,000 Shares of iRadimed Corp (IRMD)

Hilda Scharen-guivel, a Director at iRadimed Corp (IRMD), sold 3,000 shares of the company on June 4, 2026, reducing her holdings to 5,598 shares. This sale contributes to a pattern of 41 insider sells and no buys over the past year. iRadimed Corp, trading at $95 per share, is co

Tone
Negative 36/100
Event
Market update
Published
05 Jun 2026 03:09
Source
GuruFocus
Stock Titan Direct company coverage

IRADIMED (IRMD) director sells 3,000 shares in open-market trades

IRADIMED CORP director Hilda Frederique Scharen-Guivel sold 3,000 shares of Common Stock in open-market transactions for $95.00 per share on June 4, 2026. This transaction represents a net sale of $285,000 and is categorized as negative filing sentiment. The shares she still hold

Tone
Negative 34/100
Event
Market update
Published
04 Jun 2026 20:10
Source
Stock Titan
Stock Titan Direct company coverage

IRMD (NASDAQ: IRMD) files notice to resell 285,000 common shares

Iradimed Corp (IRMD) has filed a Form 144 notice with the SEC, indicating a proposed sale of 285,000 shares of common stock. The filing also notes that 12,783,035 shares were outstanding as of June 4, 2026, and references RSU vesting events in 2023 and 2024. This form serves as a

Tone
Neutral 50/100
Event
Market update
Published
04 Jun 2026 17:10
Source
Stock Titan
Investing.com Direct company coverage

Iradimed corp CEO Roger Susi sells $226,507 in IRMD shares

IRADIMED CORP (NASDAQ:IRMD) CEO Roger E. Susi sold 2,500 shares of common stock totaling $226,507 on June 1, 2026, through the Phillip Susi 2008 Dynasty Trust under a Rule 10b5-1 trading plan. These sales occurred after a strong 61.5% return for IRMD stock and follow the company'

Tone
Neutral 50/100
Event
Market update
Published
02 Jun 2026 18:39
Source
Investing.com
Stock Titan Direct company coverage

IRADIMED (IRMD) CEO-linked trust sells 2,500 shares under 10b5-1 plan

A trust linked to Roger E. Susi, CEO of IRADIMED (IRMD), indirectly sold 2,500 shares of common stock on June 1, 2026, under a pre-arranged Rule 10b5-1 trading plan. The shares were sold in multiple trades at weighted average prices between $88.68 and $91.91. After these transact

Tone
Negative 30/100
Event
Market update
Published
02 Jun 2026 18:39
Source
Stock Titan